News | Clinical Decision Support | February 05, 2019

Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support

Planned software designed to sort and score cases automatically with Transpara deep learning technology from ScreenPoint Medical

Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support

February 4, 2019 — Siemens Healthineers showcased the new planned artificial intelligence (AI)-based features with its mammography reading and reporting solution, syngo.Breast Care, at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago.1 These features are designed to provide physicians with interactive decision support.

AI features can help assist clinicians, particularly in cancer screening. A large number of mammograms are performed each day to screen for breast cancer, which means radiologists must accurately interpret hundreds of images daily. Additionally, the increased use of 3-D breast tomosynthesis adds to the number of images to be read. The new version of syngo.Breast Care is designed to give radiologists interactive clinical decision support.

AI-based algorithms are designed to help evaluate individual lesions and provide a system evaluation for 2-D mammograms or tomosynthesis. A peer-reviewed scientific study2 demonstrated increased sensitivity and specificity with the use of AI-based support.

Also, the planned software is designed to sort cases automatically and score those cases with a numerical value between 1 and 10. The case score is designed to take into account any existing lesions, microcalcifications and other abnormalities.   

syngo.Breast Care’s planned new SmartSort technology is designed for radiologists to rank exams according to their preferences based on these case scores. For example, critical cases can be moved immediately to the top to receive priority.

Siemens Healthineers collaborated with ScreenPoint Medical and plans to integrate interactive decision support in syngo.Breast Care. The company’s mammography reading software, Transpara, is based on deep learning and has been trained with over 1 million images.

Transpara received FDA 510(k) clearance for 2-D reading in late November.

For more information: www.usa.siemens.com/healthcare

References

1. Syngo.Breast Care VB40 - powered by Transpara, ScreenPoint Medical - is currently under development. It is not for sale in the U.S. Its future availability cannot be guaranteed.

2 Rodriguez-Ruiz A., Gubern-Merida A., Lang K., et al.: Detecting breast cancer in mammography: a deep learning-based computer system versus 101 radiologists (RSNA abstract 2018).

Related Content

Videos | Artificial Intelligence | July 22, 2021
This is an overview of trends and technologies in radiology...
SurveyVitals, a leading patient experience analytics provider, announced it has joined forces with the Radiology Business Management Association (RBMA) to launch Postmarks, a real-time patient and partner feedback software solution
News | Patient Engagement | July 22, 2021
July 22, 2021 — SurveyVitals, a leading patient experie
This change will be debuted at HIMSS 2021, and Vital will be exhibiting as Canon Medical for the first time
News | Information Technology | July 22, 2021
July 22, 2021 — Canon Medical Systems Corpora
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. 

News | July 21, 2021
July 21, 2021 — Artificial int...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed
Volpara now holds 98 granted patents across 27 countries
News | Breast Imaging | July 16, 2021
July 16, 2021 — Volpara has recently been granted another patent by the...
According to ARRS’ American Journal of Roentgenology (AJR), return to routine screening for BI-RADS 3 lesions on supplemental automated whole-breast US (ABUS) substantially reduces the recall rate, while being unlikely to result in adverse outcome

Normal right mediolateral oblique (A) and craniocarudal (B) view screening mammograms demonstrate density C breasts. Coronal (C), transverse (D), and reconstructed lateral (E) views from supplemental automatic breast ultrasound (ABUS) demonstrates 7 mm circumscribed slightly hypoechoic circumscribed lesion at 11 o’clock position in right breast. Lesion was classified as BI-RADS 3. Patient has undergone yearly mammograms for 4 years following the ABUS examination with no breast cancer diagnosis.

News | Breast Imaging | July 16, 2021
July 16, 2021 —...